N-Acetylcysteine Use in Older Adults with COPD and Acute Liver Failure

Primary Indications in Older Adults

The American Thoracic Society recommends NAC 600 mg twice daily orally for older adults with moderate to severe COPD (GOLD II-III) who continue to have ≥2 exacerbations per year despite optimal inhaled bronchodilator and corticosteroid therapy, with a 22% reduction in exacerbation rate (1.16 vs 1.49 exacerbations, RR 0.78) 1
NAC appears more effective in moderate COPD (GOLD II) compared to severe disease (GOLD III), with longer time to first exacerbation in the moderate group, due to its mucolytic action through cleavage of disulfide bonds in respiratory secretions, plus antioxidant and immunologic effects 1
The mechanism of NAC involves mucolytic action through cleavage of disulfide bonds in respiratory secretions, plus antioxidant and immunologic effects, as supported by the American College of Chest Physicians [2] [3]

NAC improves transplant-free survival (64% vs 26%, OR 4.81) and overall survival (76% vs 59%, OR 2.30) in acute liver failure from any cause, not just acetaminophen, as recommended by the European Association for the Study of the Liver 4
Post-transplant survival is also significantly improved (85.7% vs 71.4%, OR 2.44) with NAC treatment, as supported by the American Association for the Study of Liver Diseases 4

The standard dose of NAC is 600 mg orally twice daily for ongoing chronic use in COPD prevention, with no specific dose adjustment required for age alone, though renal function should be monitored, as recommended by the American Heart Association [1] [5]
NAC is well-tolerated with rare adverse gastrointestinal effects even with prolonged use, and has low toxicity even when combined with other treatments, as supported by the American College of Cardiology 1

While NAC reduces COPD exacerbations, it has not been shown to significantly impact mortality, which should inform discussions about indefinite use, with a combined odds ratio for exacerbation prevention of 0.61 (95% CI 0.37-0.99), representing moderate-quality evidence, as reported by the Cochrane Review 1
NAC has a low toxicity profile, with adverse effects primarily gastrointestinal (nausea, vomiting, diarrhea), and rare skin rash (<5%) or transient bronchospasm (1-2%), as supported by the European Respiratory Society 4

The European Respiratory Society suggests oral mucolytic therapy for patients with moderate or severe airflow obstruction and exacerbations despite optimal inhaled therapy, implying chronic ongoing use 6, 7
High-dose oral NAC at 600 mg twice daily has been studied and recommended for ongoing use in patients with moderate to severe chronic respiratory conditions and history of two or more exacerbations in the previous 2 years 6

NAC is generally well-tolerated with rare adverse gastrointestinal effects, even with prolonged use 6
NAC has low toxicity even when combined with other treatments, making it suitable for chronic administration 6

Ongoing therapy is appropriate for chronic conditions, with high-dose therapy showing greater efficacy in reducing exacerbations over time 6, 7
NAC appears more effective in patients with moderate chronic respiratory conditions compared to severe disease, which may influence duration decisions 6

While NAC effectively reduces exacerbations in chronic respiratory conditions, it has not been shown to significantly impact mortality, which should inform discussions about indefinite use 6
The Cystic Fibrosis Foundation found insufficient evidence for chronic inhaled NAC in cystic fibrosis patients, with no demonstrated clinical benefit 8